BioPhy

🌎 Incredible news: BioPhy has been named to Fast Company's World Changing Ideas List! We're honored to be recognized among organizations making a difference in the world. https://www.biophy.ai/wci #FCWorldChangingIdeas #AIdrugdevelopment #AIforgood

How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come Great article on MedCity News about the role of generative AI in the pharmaceutical industry. Dave Latshaw II, PhD, MBA emphasizes that “generative AI will not only accelerate the drug development process but also enhance our understanding of complex diseases.” This technology is poised to transform how we approach drug development, making it more efficient and precise. At BioPhy, we’re excited to leverage these advancements to drive innovation in healthcare! Check out the full article here: https://lnkd.in/gsXcRfcG #Pharma #DrugDevelopment #AI #Innovation #Biotechnology #AIforGood

Overcoming Pharma’s Major Pain Points and Pitfalls With AI A growing share of capital in the discovery space is now directed towards artificial intelligence, poised to revolutionize how we identify and optimize biological modules. As this technology continues to accelerate discovery processes, companies must prepare for increased productivity. However, expanding capabilities brings challenges—namely, the limited availability of skilled professionals and the high costs of recruitment. While AI is driving efficiency, its true potential lies in tackling some of pharma’s biggest bottlenecks: 1️⃣ Costly Clinical Trials: AI can shorten trial durations, optimize resources, and predict outcomes—cutting costs and speeding up drug development. 2️⃣ Delayed Commercialization: Transitioning molecules from discovery to approval involves many moving parts. AI enhances workflows across regulatory, quality, and clinical operations, ensuring smoother transitions and faster paths to market. 3️⃣ Limited Lifecycles: AI can uncover new therapeutic uses for existing drugs, maximizing a product’s impact and commercial viability. By adopting AI, we’re entering a new era of faster, cost-effective drug development and broader therapeutic applications, ultimately bringing life-saving treatments to patients more quickly. The future is bright for both pharma and patients alike. For more information see this Op-ed in MedCity News by our CEO Dave Latshaw II, PhD, MBA, BioPhy https://lnkd.in/g-Vtx_VN #AI #Pharma #DrugDevelopment #Innovation #Healthcare #AIforgood

The BioPhy team is excited to announce that we'll be kicking off the 2025 year by sponsoring the RAPS San Francisco Chapter meeting in San Francisco featuring Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research (CBER) at the FDA. The meeting will be held on January 12, 2025 from 6-8pm. Register via this link here: https://lnkd.in/g9vszmmc Our leadership team including CEO Dave Latshaw II, PhD, MBA and Scott Kobayashi will be in attendance!

Thank you to the TheVax and Ted Lindsley for this great interview. We appreciate you highlighting the work we are doing at BioPhy. Dave Latshaw II, PhD, MBA #aiforgood

Honored to have BioPhy involved in an insightful panel at The Wharton School WEMBA Alumni Reunion, led by Professor Daniel Rock. The discussion, featuring our CEO Dave Latshaw II, PhD, MBA alongside other Wharton alumni at the cutting edge of AI, explored how artificial intelligence is reshaping industries and creating new opportunities for innovation. Dave shared BioPhy's mission to accelerate the development of therapies to patients using advanced AI, and it was inspiring to hear from fellow alumni who are leading similar transformations in their fields. The conversation highlighted the importance of collaboration and continuous learning in this rapidly evolving landscape. Excited for what’s ahead as we continue to push the boundaries of AI! Credit goes to the amazing Audrey Greenberg for the photo! #WhartonAlumni #AI #Innovation #BioPhy #AIforgood

Come join this great event hosted by Philly Builds Bio+

BioPhy is looking forward to Regulatory Affairs Professionals Society (RAPS) Convergence 2024 next week. Steven Truong and Scott Kobayashi will be in Long Beach for the conference and are excited to showcase BioPhy's AI-enabled Drug Development and Regulatory Intelligence platform. #rapsconvergence2024

Learn more about how Pharma is leveraging AI to get critical therapies to patients faster.

Demand is growing and we are scaling up to meet the needs of our pharma partners. We will be hiring in key areas, with a focus on expanding our development, product, and customer relations teams. 🔍 What we're looking for: Experienced professionals Positions open to candidates in the US and EU (remote) Stay tuned for detailed role descriptions in the coming weeks. If you're passionate about innovation in the pharmaceutical industry and ready for your next challenge, we want to hear from you! #BioPhy #Hiring #Pharmaceuticals #RemoteWork